Banner

Mouse VEGFR2 ELISA Kit (RMEK-0154021)

Cat. No.: RMEK-0154021

Category: ELISA Kits

INQUIRY 1 x 96 tests
Mouse VEGFR2 ELISA Kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of VEGFR2 protein in cell culture supernatant, cit plasma, edta plasma, hep plasma, and serum. The technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time.

Product Features

Species Reactivity Mouse
Detection Method Colorimetric
Assay Duration One step assay
Assay Time 1.5 h
Assay Type Sandwich (quantitative)
Precision Intra-Assay-Serum-5-6.4%; Inter-Assay-Serum-3-6.9%
Sensitivity 28.8 pg/mL
Range 78.13 pg/mL - 5000 pg/mL
Sample Type Cell culture supernatant, Cit plasma, EDTA Plasma, Hep Plasma, Serum
Recovery Cell culture supernatant-120-113% - 124%; Serum-106-102% - 110%; Hep Plasma-101-90% - 107%; EDTA Plasma-101-99% - 102%; Cit plasma-112-106% - 117%
Key Features One-wash 90 minute protocol; Sensitivity: 28.8 pg/mL; Range: 78.13 pg/mL - 5000 pg/mL; Sample type: Cell culture supernatant, Cit plasma, EDTA Plasma, Hep Plasma, Serum; Detection method: Colorimetric; Assay type: Sandwich (quantitative); Reacts with: Mouse

Target Information

Target Symbol VEGFR2
UniProt ID P35968
Function Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Cellular Localization Membrane.
Post-transcriptional Modifications Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
Involvement in Disease Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI). HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.

Storage & Shipping

Storage Store at 2-8°C
Shipping Gel Packs
Stability The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.

For research use only. Not for clinical use.